Cargando…

Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients

BACKGROUND: Chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are controversial in the treatment of patients with brain metastases from non-small-cell lung cancer (NSCLC). METHODS: We retrospectively studied the effects of solely localized treatment or localized tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yun, Huang, Zhiyu, Fang, Luo, Miu, Lulu, Lin, Nengming, Gong, Lei, Yu, Haifeng, Yang, Haiyan, Mao, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862699/
https://www.ncbi.nlm.nih.gov/pubmed/24353431
http://dx.doi.org/10.2147/OTT.S52172
_version_ 1782295776157761536
author Fan, Yun
Huang, Zhiyu
Fang, Luo
Miu, Lulu
Lin, Nengming
Gong, Lei
Yu, Haifeng
Yang, Haiyan
Mao, Weimin
author_facet Fan, Yun
Huang, Zhiyu
Fang, Luo
Miu, Lulu
Lin, Nengming
Gong, Lei
Yu, Haifeng
Yang, Haiyan
Mao, Weimin
author_sort Fan, Yun
collection PubMed
description BACKGROUND: Chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are controversial in the treatment of patients with brain metastases from non-small-cell lung cancer (NSCLC). METHODS: We retrospectively studied the effects of solely localized treatment or localized treatment in combination with chemotherapy and/or EGFR tyrosine kinase inhibitors on outcomes in 210 NSCLC patients with brain metastases. The effects of treatment modality, Karnofsky performance status, age, primary tumor histology, number of brain metastases, and other factors on survival time were analyzed, and the robustness of two prognostic indices, ie, recursive partitioning analysis and graded prognostic assessment, was evaluated. RESULTS: The median survival time in patients with systemic medication and localized treatments was higher than in those with localized treatments alone (11 versus 3 months, P=0.000). Within the systemic medication group, median survival time was significantly longer for EGFR tyrosine kinase inhibitors than for other types of chemotherapy (12 versus 9 months, P=0.002). In the EGFR tyrosine kinase inhibitor group, median survival time for patients with EGFR gene mutation was 20 months versus 8 months for those with the wild-type EGFR gene. The median survival time with pemetrexed was significantly higher than with other chemotherapies (13 versus 7 months, P=0.006). In multivariate analysis, the prognosis was significantly correlated with treatment modality (P=0.000), Karnofsky performance status (P=0.000), number of brain metastases (P=0.001), and histologic tumor type (P=0.007). In the graded prognostic assessment model, survival curves for the subgroups showed clear separations. CONCLUSION: NSCLC patients with brain metastasis benefited from pemetrexed and/or tyrosine kinase inhibitors along with localized treatments, and the graded prognostic assessment index is a robust model for prognostic evaluation.
format Online
Article
Text
id pubmed-3862699
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-38626992013-12-18 Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients Fan, Yun Huang, Zhiyu Fang, Luo Miu, Lulu Lin, Nengming Gong, Lei Yu, Haifeng Yang, Haiyan Mao, Weimin Onco Targets Ther Original Research BACKGROUND: Chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are controversial in the treatment of patients with brain metastases from non-small-cell lung cancer (NSCLC). METHODS: We retrospectively studied the effects of solely localized treatment or localized treatment in combination with chemotherapy and/or EGFR tyrosine kinase inhibitors on outcomes in 210 NSCLC patients with brain metastases. The effects of treatment modality, Karnofsky performance status, age, primary tumor histology, number of brain metastases, and other factors on survival time were analyzed, and the robustness of two prognostic indices, ie, recursive partitioning analysis and graded prognostic assessment, was evaluated. RESULTS: The median survival time in patients with systemic medication and localized treatments was higher than in those with localized treatments alone (11 versus 3 months, P=0.000). Within the systemic medication group, median survival time was significantly longer for EGFR tyrosine kinase inhibitors than for other types of chemotherapy (12 versus 9 months, P=0.002). In the EGFR tyrosine kinase inhibitor group, median survival time for patients with EGFR gene mutation was 20 months versus 8 months for those with the wild-type EGFR gene. The median survival time with pemetrexed was significantly higher than with other chemotherapies (13 versus 7 months, P=0.006). In multivariate analysis, the prognosis was significantly correlated with treatment modality (P=0.000), Karnofsky performance status (P=0.000), number of brain metastases (P=0.001), and histologic tumor type (P=0.007). In the graded prognostic assessment model, survival curves for the subgroups showed clear separations. CONCLUSION: NSCLC patients with brain metastasis benefited from pemetrexed and/or tyrosine kinase inhibitors along with localized treatments, and the graded prognostic assessment index is a robust model for prognostic evaluation. Dove Medical Press 2013-12-04 /pmc/articles/PMC3862699/ /pubmed/24353431 http://dx.doi.org/10.2147/OTT.S52172 Text en © 2013 Fan et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Fan, Yun
Huang, Zhiyu
Fang, Luo
Miu, Lulu
Lin, Nengming
Gong, Lei
Yu, Haifeng
Yang, Haiyan
Mao, Weimin
Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
title Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
title_full Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
title_fullStr Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
title_full_unstemmed Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
title_short Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
title_sort chemotherapy and egfr tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862699/
https://www.ncbi.nlm.nih.gov/pubmed/24353431
http://dx.doi.org/10.2147/OTT.S52172
work_keys_str_mv AT fanyun chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients
AT huangzhiyu chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients
AT fangluo chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients
AT miululu chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients
AT linnengming chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients
AT gonglei chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients
AT yuhaifeng chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients
AT yanghaiyan chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients
AT maoweimin chemotherapyandegfrtyrosinekinaseinhibitorsfortreatmentofbrainmetastasesfromnonsmallcelllungcancersurvivalanalysisin210patients